Jubilant Life Consolidated December 2020 Net Sales at Rs 1,771.34 crore, down 23.49% Y-o-Y

Jubilant Life Sciences Q3 PAT seen up 14.9% YoY to Rs. 238 cr: Prabhudas Lilladher

Net Sales are expected to increase by 10.4 percent Y-o-Y (up 7.6 percent Q-o-Q) to Rs. 2,315.2 crore, according to Prabhudas Lilladher.

Jubilant Life Sciences raises Rs 90 crore through commercial papers

New Delhi, Nov 26 Drug firm Jubilant Life Sciences on Thursday said it has issued commercial papers worth Rs 90 crore. Tenure of the instrument i..

Accumulate Jubilant Life Sciences; target of Rs 752: Prabhudas Lilladher

Prabhudas Lilladher recommended accumulate rating on Jubilant Life Sciences with a target price of Rs 752 in its research report dated November 05, 2020.

Buy Jubilant Life Sciences; target of Rs 855: Motilal Oswal

Motilal Oswal is bullish on Jubilant Life Sciences recommended buy rating on the stock with a target price of Rs 855 in its research report dated November 04, 2020.

Buy Jubilant Life Sciences; target of Rs 850: ICICI Direct

ICICI Direct is bullish on Jubilant Life Sciences recommended buy rating on the stock with a target price of Rs 850 in its research report dated November 08, 2020.

Jubilant Life Standalone September 2020 Net Sales at Rs 760.75 crore, up 0.42% Y-o-Y

Jubilant Life Sciences Q2 net profit declines 10% to Rs 224 crore

The company had posted a net profit of Rs 249.39 crore for the corresponding period of the previous fiscal, Jubilant Life Sciences said in a BSE filing.

Jubilant Life Consolidated September 2020 Net Sales at Rs 2,374.89 crore, up 4.81% Y-o-Y

Buy Jubilant Life Sciences; target of Rs 975: Motilal Oswal

Motilal Oswal is bullish on Jubilant Life Sciences recommended buy rating on the stock with a target price of Rs 975 in its research report dated September 05, 2020.

Sell Jubilant Life Sciences; target of Rs 446: Prabhudas Lilladher

Prabhudas Lilladher is bearish on Jubilant Life Sciences has recommended sell rating on the stock with a target price of Rs 446 in its research report dated September 07, 2020.

Hold Jubilant Life Sciences: target of Rs 822: ICICI Securities

ICICI Securities recommended hold rating on Jubilant Life Sciences with a target price of Rs 822 in its research report dated September 05, 2020.

Jubilant Life Sciences shares fall 5% after Q1 profit tumbles 52%

Consolidated total revenue from the operations of the company stood at Rs 1,892.92 crore for the quarter under consideration. It was Rs 2,181.86 crore for the same period a year ago, the company said.

Jubilant Life Sciences presents 1,000 vials of Remdesivir to Uttar Pradesh CM Yogi Adityanath

The drug is being made available to over 1,000 hospitals providing COVID-19 treatment in India through the company's distribution network, Jubilant Life Sciences said in a statement.

Jubilant Life hits 52-week high on DCGI nod for Remdesivir; Rakesh Jhunjhunwala raises stake in June quarter

The company's subsidiary Jubilant Generics has received the approval from Drug Controller General of India (DCGI) to manufacture and market investigational drug Remdesivir 100 mg/vial (lyophilized injection).

Jubilant Life share at 52-week high as Rakesh Jhunjhunwala raises stake

Rakesh Radheshyam Jhunjhunwala held 4.41 percent stake (or 70.25 lakh equity shares) in the pharma company as per March shareholding pattern available on exchanges.

Buy Jubilant Life Sciences; target of Rs 867: Anand Rathi

Anand Rathi is bullish on Jubilant Life Sciences has recommended buy rating on the stock with a target price of Rs 867 in its research report dated June 12, 2020.

Hold Jubilant Life Sciences; target of Rs 414: Prabhudas Lilladher

Prabhudas Lilladher recommended Hold rating on Jubilant Life Sciences with a target price of Rs 414 in its research report dated Jun 01, 2020.

Jubilant Life Consolidated March 2020 Net Sales at Rs 2,391.41 crore, up 0.24% Y-o-Y

Jubilant Life Standalone March 2020 Net Sales at Rs 791.36 crore, down 8.53% Y-o-Y

Buy Jubilant Life Sciences; target of Rs 550: ICICI Direct

ICICI Direct is bullish on Jubilant Life Sciences has recommended buy rating on the stock with a target price of Rs 550 in its research report dated Jun 01, 2020.

Buy Jubilant Life Sciences; target of Rs 515: Motilal Oswal

Motilal Oswal is bullish on Jubilant Life Sciences has recommended buy rating on the stock with a target price of Rs 515 in its research report dated May 30, 2020.

Jubilant Life Sciences posts Rs 260.49 crore profit for March quarter

Consolidated revenue from operations stood at Rs 2,391.41 crore for the quarter under consideration as against Rs 2,385.58 crore for the same period year ago, it added.

Jubilant Life Sciences signs agreement with Gilead for remdesivir

Under the licencing agreement, the company has the right to receive technology transfer of the Gilead manufacturing process to scale up production.

Jubilant Life jumps 5% as Rakesh Jhunjhunwala raises stake to 4.41% in March quarter

In December quarter, he held 3.45 percent stake in the company, which meant the shareholding increased by 0.96 percent during the March quarter.